| Literature DB >> 25381468 |
Nina Jullum Kise1, Jon Olav Drogset, Arne Ekeland, Einar Andreas Sivertsen, Stig Heir.
Abstract
PURPOSE: Multiple techniques and implants are available for all-inside meniscal repair, but the knowledge about their failure rates and functional outcome is still incomplete. The hypothesis was that there might be differences between meniscal arrows and suture devices regarding reoperation rates and functional outcome. Thereby, the aim of this study was to compare clinical results following repair with the Biofix(®) arrows or the FasT-Fix(®) suture devices.Entities:
Mesh:
Year: 2014 PMID: 25381468 PMCID: PMC4284382 DOI: 10.1007/s00167-014-3423-5
Source DB: PubMed Journal: Knee Surg Sports Traumatol Arthrosc ISSN: 0942-2056 Impact factor: 4.342
Fig. 1Flow chart
Baseline data
| Baseline | Biofix®-group | FasT-Fix®-group |
|---|---|---|
| Number | 21 Patients | 25 Patients |
| Age | ||
| Median (range) | 26.9 years (19.4–39.8) | 25.5 years (18.7–40.0) |
| Gender | 9 Men/12 women | 17 Men/8 women |
| Knee | 9 Right/12 left | 16 Right/9 left |
| Meniscus | 20 Medial/1 lateral | 24 Medial/1 lateral |
| Length of meniscal tear | ||
| Median (range) | 20–30 mm (10–40 mm) | 20–30 mm (10–40 mm) |
| ACL pathology Total | 5 Patients | 7 Patients |
| Earlier ACL-reconstructed | 2 Patients | 3 Patients |
| Concomitant ACL-reconstructions | 2 Patients | 3 Patients |
| Remained untreated | 1 Patient | 1 Patient |
| Other concomitant injuries | Cartilage injuries 2 patients Osteoarthritis 2 patients | Cartilage injuries 4 patients |
| Time injury-surgery | ||
| Median (range) | 4.5 months (0.2–29.7) | 4.1 months (0.2–120.0) |
Fig. 2Survival function following meniscal repair with Biofix® meniscal arrows and FasT-Fix® sutures. Each step represents a reoperation due to rerupture or failed primary healing
Fig. 3KOOS profiles (expressed as median values) for the two treatment groups preoperatively and at 2-year follow-up (p < 0.01 for each subscale in both groups)
Fig. 4The KOOS profiles (expressed as median values) of the treatment groups at 2-year follow-up did not differ significantly from the KOOS profile of a reference population (grey line)
KOOS and Tegner activity scale scores at baseline and follow-ups at 3 and 6 months and 2 years in the two treatment groups
| Scores | Group | Baseline | 3-month follow-up |
| 6-month follow-up |
| 2-year follow-up |
|
|---|---|---|---|---|---|---|---|---|
KOOS Pain Median (range) | Biofix® | 61 (36–86) | 72 (53–97) | n.s | 94 (54–100) | 0.041 | 92 (69–100) | n.s |
| FasT-Fix® | 63 (31–94) | 83 (72–92) | 82 (47–97) | 94 (25–100) | ||||
KOOS Symptoms Median (range) | Biofix® | 75 (46–79) | 71 (46–96) | n.s. | 86 (54–100) | n.s | 89 (68–100) | n.s |
| FasT-Fix® | 70 (28–89) | 80 (68–86) | 77 (61–96) | 95 (57–100) | ||||
KOOS ADL Median (range) | Biofix® | 75 (41–99) | 94 (56–100) | n.s. | 100 (71–100) | n.s | 99 (78–100) | n.s |
| FasT-Fix® | 68 (54–100) | 91 (78–99) | 88 (57–100) | 98 (44–100) | ||||
KOOS Sport-Rec Median (range) | Biofix® | 30 (0–55) | 40 (5–85) | n.s. | 75 (5–95) | n.s | 65 (25–100) | n.s |
| FasT-Fix® | 40 (0–90) | 60 (0–75) | 68 (35–95) | 85 (50–100) | ||||
KOOS QOL Median (range) | Biofix® | 38 (6–63) | 50 (19–75) | n.s. | 81 (6–94) | n.s | 75 (25–100) | n.s |
| FasT-Fix® | 41 (0–83) | 47 (31–88) | 63 (31–94) | 78 (6–100) | ||||
Tegner activity Score Median (range) | Biofix® | 4 (0–9) | 4 (0–9) | <0.01 | 4 (2–9) | 0.046 | 5 (2–9) | n.s |
| FasT-Fix® | 4 (0–10) | 3 (0–9) | 3 (0–9) | 4 (1–9) |
Results from follow-ups at 6 weeks and 1 year are not listed because there were no statistical differences between the groups